Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21630148 | 0.89 | POLB (0.59) | POLBGAAATMMAPTSMN1; SMN2 | |
| SCHEMBL10117151 | 0.87 | POLB (0.60) | POLBGAAATMMAPTSMN1; SMN2 | |
| SCHEMBL8867542 | 0.86 | SMN1; SMN2 (0.49) | POLBMAPTSMN1; SMN2RAB9AHPGD | |
| SCHEMBL8866798 | 0.85 | POLB (0.57) | POLBGAAATMMAPTSMN1; SMN2 | |
| SCHEMBL13652580 | 0.85 | GAA (0.59) | POLBGAAATMMAPTSMN1; SMN2 | |
| SCHEMBL13989319 | 0.84 | GAA (0.73) | POLBGAAATMMAPTSMN1; SMN2 | |
| SCHEMBL2619349 | 0.84 | POLB (0.76) | POLBGAAATMSMN1; SMN2RAB9A | |
| SCHEMBL16691055 | 0.84 | GAA (0.69) | POLBGAAMAPTSMN1; SMN2RAB9A | |
| SCHEMBL11983728 | 0.84 | POLB (0.71) | POLBGAAMAPTSMN1; SMN2RAB9A | |
| SCHEMBL12285463 | 0.82 | GAA (0.61) | POLBGAAATMMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703735-B2 | 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2020-07-07 | — | — | US | disclosed |
| US-20200031794-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-5686484-A | ANTHELMINTICS, ACARICIDES, INSECTICIDES | SANKYO CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031794-A1 | 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | POLRMT, COX4I1, UQCRC2 | POLB 43/4885GAA 926/4885ATM 2228/4885 |
| US-10703735-B2 | 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | POLRMT, COX4I1, UQCRC2 | POLB 43/4885GAA 926/4885ATM 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.